KRRO
Korro Bio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About KRRO
Korro Bio, Inc.
A company that develops therapeutics to treat patients suffering from sensorineural hearing loss
Biological Technology
11/13/2014
10/03/2019
NASDAQ Stock Exchange
104
12-31
Common stock
60 First Street, 2nd Floor, Suite 250, Cambridge, MA 02141
--
Korro Bio, Inc., a Delaware corporation, was incorporated on November 13, 2014. The company is a biopharmaceutical company whose mission is to discover, develop and commercialize a new class of genetic medicines based on editing RNA that can treat rare and highly prevalent diseases. The company is generating a portfolio of differentiated programs designed to leverage the body's natural RNA editing process for precise but short-lived single-base editing.
Company Financials
EPS
KRRO has released its 2025 Q3 earnings. EPS was reported at -1.92, versus the expected -2.68, beating expectations. The chart below visualizes how KRRO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
KRRO has released its 2025 Q3 earnings report, with revenue of 1.09M, reflecting a YoY change of NaN%, and net profit of -18.06M, showing a YoY change of 13.99%. The Sankey diagram below clearly presents KRRO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
